Recruiting
Asthma
RecruitingInvestigational
A Study of Brenipatide Compared to Placebo for Adults with Uncontrolled Moderate to Severe Asthma
Investigational
Countries:
France
France- Participants:18–64 years
- Substances:LY3537031
Find therapies in clinical trials near you – page 6
- recruiting
- 3 962
- countries
- 28
- conditions
- 2 101
3 962 trials recruiting28 European countries2 101 conditions coveredUpdated today
10 246 trials match your criteria
Recruiting
COVID-19
RecruitingInvestigational
A study testing molnupiravir in adults with COVID-19 who are not hospitalized and are at high risk for serious illness
Investigational
- Disease:COVID-19
- Substances:MOLNUPIRAVIR
Countries:
Bulgaria
Bulgaria- Participants:18–64 years · 65+ years
- Substances:MOLNUPIRAVIR
Recruiting
Psoriasis
RecruitingRegistered drugNo placebo
Long-term safety study of deucravacitinib compared to ustekinumab in adults with moderate to severe plaque psoriasis
Registered drugNo placebo
- Disease:Psoriasis
- Substances:DeucravacitinibUstekinumab
Countries:
Belgium
Belgium- Participants:18–64 years · 65+ years
- Substances:Deucravacitinib
Recruiting
Colitis ulcerative
RecruitingInvestigational
A Study of Long-acting Antibodies SPY001-001 and SPY002 Alone and Combined for Adults with Moderate to Severe Ulcerative Colitis
Investigational
- Disease:Colitis ulcerative
- Substances:SPY002
Countries:
Austria
Austria- Participants:18–64 years · 65+ years
- Substances:SPY002
Recruiting
Investigational
A study of navenibart for long-term safety in patients with hereditary angioedema
Investigational
- Disease:Hereditary angioedema with C1 esterase inhibitor deficiencyHereditary angioedema
- Substances:NAVENIBART
Countries:Austria
Austria- Participants:0–17 years · 18–64 years · 65+ years
- Substances:NAVENIBART
Recruiting
Pancreatic neuroendocrine tumour
RecruitingRegistered drugNo placebo
A study comparing XL092 versus everolimus in patients with previously treated advanced or metastatic neuroendocrine tumors
Registered drugNo placebo
- Disease:Pancreatic neuroendocrine tumour
- Substances:EverolimusN-(4-Fluorophenyl)-N-(4-((7-Methoxy-6-(Methylcarbamoyl)Quinolin-4- Yl)Oxy)Phenyl)Cyclopropane-1,1-Dicarboxamide
Countries:Austria
Austria- Participants:18–64 years · 65+ years
- Substances:Everolimus
Recruiting
Colitis ulcerative
RecruitingInvestigational
A study of duvakitug for patients with moderately to severely active ulcerative colitis to see if it works and is safe as maintenance therapy
Investigational
- Disease:Colitis ulcerative
- Substances:Duvakitug
Countries:Austria
Austria- Participants:0–17 years · 18–64 years · 65+ years
- Substances:Duvakitug
Recruiting
Colitis ulcerative
RecruitingInvestigational
A study testing duvakitug for patients with moderately to severely active ulcerative colitis
Investigational
- Disease:Colitis ulcerative
- Substances:Duvakitug
Countries:Austria
Austria- Participants:0–17 years · 18–64 years · 65+ years
- Substances:Duvakitug
Recruiting
Palmoplantar pustulosis
RecruitingRegistered drug
A Study Testing How Well Bimekizumab Works and How Safe It Is for Adults with Palmoplantar Pustulosis
Registered drug
- Disease:Palmoplantar pustulosis
- Substances:Bimekizumab
Countries:
Czechia
Czechia- Participants:18–64 years · 65+ years
- Substances:Bimekizumab
Recruiting
Cachexia
RecruitingInvestigational
A Study of Visugromab Compared to Placebo in Patients with Cancer-Related Cachexia to Test How Well It Works and How Safe It Is
Investigational
- Disease:Cachexia
- Substances:VISUGROMAB
Countries:Bulgaria
Bulgaria- Participants:18–64 years · 65+ years
- Substances:VISUGROMAB
Recruiting
Uveal melanoma
RecruitingInvestigationalNo placebo
A Study of Darovasertib Before Surgery or Radiation Therapy for Patients with Early-Stage Uveal Melanoma That Has Not Spread
InvestigationalNo placebo
- Disease:Uveal melanoma
- Substances:Darovasertib
Countries:Austria
Austria- Participants:18–64 years · 65+ years
- Substances:Darovasertib
Recruiting
Cardiovascular disorder+1
RecruitingInvestigational
Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk
Investigational
- Disease:Cardiovascular disorderHypertension
- Substances:ZILEBESIRAN
Countries:Austria
Austria- Participants:18–64 years · 65+ years
- Substances:ZILEBESIRAN